Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen
Haematologica. 2024 Sep 5.
doi: 10.3324/haematol.2024.285837.
Online ahead of print.